Ocular Therapeutix (OCUL) Common Equity (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Common Equity of $520.0 million for Q2 2026, up 69.99% year-over-year from $305.9 million in Q2 2025, and down 10.58% on a QoQ basis from $581.6 million in Q1 2026.
Ocular Therapeutix (OCUL) Common Equity (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Common Equity for 14 years, with the latest figure at $520.0 million in Q2 2026.
- Common Equity for Q2 2026 came in at $520.0 million, up 69.99% year-over-year; the trailing twelve-month figure through Jun 2026 was $520.0 million (up 69.99% YoY), and the FY2025 annual result was $654.3 million, up 107.49% from the prior year.
- Common Equity fell to $520.0 million in Q2 2026, from $581.6 million in the prior quarter.
- Over five years, Common Equity peaked at $654.3 million in Q4 2025 and troughed at $3.1 million in Q2 2023.
- A 5-year average of $243.2 million and a median of $262.1 million in 2025 frame the typical range for Common Equity.
- The widest annual swing landed in 2023, when Common Equity tumbled 95.31%; it then surged 12135.02% in 2024.
- A 5-year view of Common Equity shows it stood at $35.4 million in 2022, then jumped by 157.59% to $91.1 million in 2023, then surged by 246.03% to $315.3 million in 2024, then jumped by 107.49% to $654.3 million in 2025, then declined by 20.52% to $520.0 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $520.0 million in Q2 2026, $581.6 million in Q1 2026, and $654.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 520.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 520.04 Mn |
| Mar 31, 2026 | 581.57 Mn |
| Dec 31, 2025 | 654.31 Mn |
| Sep 30, 2025 | 258.23 Mn |
| Jun 30, 2025 | 305.92 Mn |
| Mar 31, 2025 | 265.93 Mn |
| Dec 31, 2024 | 315.34 Mn |
| Sep 30, 2024 | 352.02 Mn |
| Jun 30, 2024 | 377.70 Mn |
| Mar 31, 2024 | 407.98 Mn |
| Dec 31, 2023 | 91.13 Mn |
| Sep 30, 2023 | 7.85 Mn |
| Jun 30, 2023 | 3.09 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | 35.38 Mn |
| Sep 30, 2022 | 46.23 Mn |
| Jun 30, 2022 | 65.80 Mn |
| Mar 31, 2022 | 79.80 Mn |
| Dec 31, 2021 | 88.00 Mn |
| Sep 30, 2021 | 87.34 Mn |